Navigation Links
STAAR Surgical Reports 33% Third Quarter Revenue Growth
Date:10/28/2008

$18,112 $2,910 $15,202

Cost of Sales 7,654 830 6,824

Gross Profit 10,458 2,080 8,378

Gross Profit Margin 57.7% 71.5% 55.1%

General and Administrative 3,480 930 2,550

Marketing and Selling 6,514 811 5,703

Research and Development 1,890 490 1,400

Loss on Settlement of Preexisting

Distribution Arrangement - - -

Total Selling, General, and

Administrative 11,884 2,231 9,653

Operating Loss (1,426) (151) (1,275)

Other Income (Expense) (585) (4) (581)

Loss Before Income Taxes (2,011) (155) (1,856)

Income Taxes 239 10 229

Net Loss $(2,250) $(165) $(2,085)

Loss Per Share $(0.08) $(0.01) $(0.07)

2008 vs. 2007

Q3 As Reported Ex-Japan

Statement of Operations 2007 $ % $ %

Change Change Change Change

Sales $13,629 $4,483 33% $1,573 12%

Cost of Sales 6,859 795 12% (35) -1%

Gross Profit 6,770 3,688 54% 1,608 24%

Gross Profit Margin 49.7% 8.1% 16% 5.4% 11%

General and Administrative 2,868 612 21% (318) -11%

Marketing and Selling 5,775 739
'/>"/>

SOURCE STAAR Surgical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. STAAR Surgical to Present at the Noble Financial Equity Conference
2. STAAR Surgicals Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification
3. STAAR Surgicals LASIK Alternative Expands U.S. Market Gains
4. STAAR Surgical Reports Solid First Quarter Progress
5. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
6. STAAR Surgical Plans Major Presence at ASCRS
7. STAAR Surgical Reports Fourth Quarter and Year End Results
8. STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show
9. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
10. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
11. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Growth in the Parkinsons Disease Drug Market Fueled by the Launch of Several New Therapies Will be Offset by Generic Erosion of Key Agents 48287 1Growth in the Parkinsons Disease Drug Market Fueled by the Launch of Several New Therapies Will be Offset by Generic Erosion of Key Agents 48287 2AssureRx Adds New CEO 12542 1AssureRx Adds New CEO 12542 2Empire BlueCross BlueShield Adds Life Insurance Becomes Full Service Benefits Provider 48280 1Empire BlueCross BlueShield Adds Life Insurance Becomes Full Service Benefits Provider 48280 2Empire BlueCross BlueShield Adds Life Insurance Becomes Full Service Benefits Provider 48280 3Empire BlueCross BlueShield Adds Life Insurance Becomes Full Service Benefits Provider 48280 4